参考文献:1.Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.CrossRef PubMed 2.Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53:2087–94.CrossRef PubMed 3.Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–7.CrossRef PubMed 4.Cancello R, Zulian A, Gentilini D, Maestrini S, Della Barba A, Invitti C, et al. Molecular and morphologic characterization of superficial- and deep-subcutaneous adipose tissue subdivisions in human obesity. Obesity (Silver Spring). 2013;21:2562–70.CrossRef 5.Monzon JR, Basile R, Heneghan S, Udupi V, Green A. Lipolysis in adipocytes isolated from deep and superficial subcutaneous adipose tissue. Obes Res. 2002;10:266–9.CrossRef PubMed 6.Walker GE, Verti B, Marzullo P, Savia G, Mencarelli M, Zurleni F, et al. Deep subcutaneous adipose tissue: a distinct abdominal adipose depot. Obesity (Silver Spring). 2007;15:1933–43.CrossRef 7.Marinou K, Hodson L, Vasan SK, Fielding BA, Banerjee R, Brismar K, et al. Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes Care. 2014;37:821–9.CrossRef PubMed 8.Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab. 2000;278:E941–8.PubMed 9.Smith SR, Lovejoy JC, Greenway F, Ryan D, deJonge L, de la Bretonne J, et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism. 2001;50:425–35.CrossRef PubMed 10.Golan R, Shelef I, Rudich A, Gepner Y, Shemesh E, Chassidim Y, et al. Abdominal superficial subcutaneous fat: a putative distinct protective fat subdepot in type 2 diabetes. Diabetes Care. 2012;35:640–7.PubMedCentral CrossRef PubMed 11.Deschenes D, Couture P, Dupont P, Tchernof A. Subdivision of the subcutaneous adipose tissue compartment and lipid-lipoprotein levels in women. Obes Res. 2003;11:469–76.CrossRef PubMed 12.Walker GE, Marzullo P, Verti B, Guzzaloni G, Maestrini S, Zurleni F, et al. Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects. Obesity (Silver Spring). 2008;16:1983–91.CrossRef 13.Walker GE, Marzullo P, Ricotti R, Bona G, Prodam F. The pathophysiology of abdominal adipose tissue depots in health and disease. Horm Mol Biol Clin Investig. 2014;19:57–74.PubMed 14.Mazaheri S, Sadeghi M, Sarrafzadegan N, Sanei H, Hekmatnia A, Tavakoli B. Correlation between body fat distribution, plasma lipids and apolipoproteins with the severity of coronary involvement in patients with stable angina. ARYA Atheroscler. 2011;6:140–3.PubMedCentral PubMed 15.Nimitphong H, Phongkitkarun S, Rattarasarn C, Kongsooksai A, Chanprasertyothin S, Bunnag PA, et al. Hepatic fat content is a determinant of postprandial triglyceride levels in type 2 diabetes mellitus patients with normal fasting triglyceride. Metabolism. 2008;57:644–9.CrossRef PubMed 16.Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.CrossRef PubMed 17.Fujikawa R, Ito C, Nakashima R, Orita Y, Ohashi N. Is there any association between subcutaneous adipose tissue area and plasma total and high molecular weight adiponectin levels? Metabolism. 2008;57:506–10.CrossRef PubMed 18.Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes. 1997;46:1579–85.CrossRef PubMed 19.Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39–48.CrossRef PubMed 20.Tordjman J, Divoux A, Prifti E, Poitou C, Pelloux V, Hugol D, et al. Structural and inflammatory heterogeneity in subcutaneous adipose tissue: relation with liver histopathology in morbid obesity. J Hepatol. 2012;56:1152–8.CrossRef PubMed 21.He H, Ni Y, Chen J, Zhao Z, Zhong J, Liu D, et al. Sex difference in cardiometabolic risk profile and adiponectin expression in subjects with visceral fat obesity. Transl Res. 2010;155:71–7.CrossRef PubMed 22.Iglesias MJ, Eiras S, Pineiro R, Lopez-Otero D, Gallego R, Fernandez AL, et al. Gender differences in adiponectin and leptin expression in epicardial and subcutaneous adipose tissue. Findings in patients undergoing cardiac surgery. Rev Esp Cardiol. 2006;59:1252–60.CrossRef PubMed 23.Lonnqvist F, Thorne A, Large V, Arner P. Sex differences in visceral fat lipolysis and metabolic complications of obesity. Arterioscler Thromb Vasc Biol. 1997;17:1472–80.CrossRef PubMed 24.Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J. 2006;70:1437–42.CrossRef PubMed 25.Lundbom J, Hakkarainen A, Lundbom N, Taskinen MR. Deep subcutaneous adipose tissue is more saturated than superficial subcutaneous adipose tissue. Int J Obes (Lond). 2013;37:620–2.CrossRef 26.McLaughlin T, Sherman A, Tsao P, Gonzalez O, Yee G, Lamendola C, et al. Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia. 2007;50:1707–15.CrossRef PubMed 27.Scaglione R, Di Chiara T, Cariello T, Licata G. Visceral obesity and metabolic syndrome: two faces of the same medal? Intern Emerg Med. 2010;5:111–9.CrossRef PubMed 28.Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A, et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism. 2003;52:1274–8.CrossRef PubMed 29.Kwon K, Jung SH, Choi C, Park SH. Reciprocal association between visceral obesity and adiponectin: in healthy premenopausal women. Int J Cardiol. 2005;101:385–90.CrossRef PubMed 30.Silha JV, Nyomba BL, Leslie WD, Murphy LJ. Ethnicity, insulin resistance, and inflammatory adipokines in women at high and low risk for vascular disease. Diabetes Care. 2007;30:286–91.CrossRef PubMed 31.Walker GE, Marzullo P, Prodam F, Bona G, Di Blasio AM. Obesity modifies expression profiles of metabolic markers in superficial and deep subcutaneous abdominal adipose tissue depots. Endocrine. 2014;46:99–106.CrossRef PubMed 32.Koistinen HA, Bastard JP, Dusserre E, Ebeling P, Zegari N, Andreelli F, et al. Subcutaneous adipose tissue expression of tumour necrosis factor-alpha is not associated with whole body insulin resistance in obese nondiabetic or in type-2 diabetic subjects. Eur J Clin Invest. 2000;30:302–10.CrossRef PubMed 33.Lee JM, Kim SR, Yoo SJ, Hong OK, Son HS, Chang SA. The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes. J Int Med Res. 2009;37:1803–12.CrossRef PubMed 34.Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation. 2007;116:1234–41.CrossRef PubMed 35.Njajou OT, Kanaya AM, Holvoet P, Connelly S, Strotmeyer ES, Harris TB, et al. Association between oxidized LDL, obesity and type 2 diabetes in a population-based cohort, the Health, Aging and Body Composition Study. Diabetes Metab Res Rev. 2009;25:733–9.PubMedCentral CrossRef PubMed 36.Indulekha K, Anjana RM, Surendar J, Mohan V. Association of visceral and subcutaneous fat with glucose intolerance, insulin resistance, adipocytokines and inflammatory markers in Asian Indians (CURES-113). Clin Biochem. 2011;44:281–7.CrossRef PubMed 37.Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia. 2005;48:2330–3.CrossRef PubMed 38.Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol. 2007;156:279–84.CrossRef PubMed 39.Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111:932–9.CrossRef PubMed 40.Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res. 2003;11:997–1001.CrossRef PubMed
作者单位:Se-Hong Kim (1) Ju-hye Chung (2) Sang-Wook Song (1) Won Sang Jung (3) Yun-Ah Lee (1) Ha-Na Kim (1)
1. Department of Family Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, 93-6 Ji-dong, Paldal-Gu, Suwon, Kyonggi-do, 442-723, Republic of Korea 2. Department of Family Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 271, Cheon Bo-ro, Uijeongbu, Gyeonggi-do, 480-717, Republic of Korea 3. Department of Radiology, College of Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, 93-6 Ji-dong, Paldal-Gu, Suwon, Kyonggi-do, 442-723, Republic of Korea
刊物主题:Diabetes; Metabolic Diseases; Endocrinology;
出版者:BioMed Central
ISSN:1758-5996
文摘
Background The deep subcutaneous adipose tissue (dSAT) is closely related to the obesity-associated complications similarly to the characteristics of visceral adipose tissue (VAT). However, the association between dSAT and metabolic syndrome (MS) is unclear. The purpose of our study was to evaluate the association of distinct abdominal adipose tissue with the cardiometabolic risk factors and MS.